Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan H Frenking

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine|July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agentJulian Zoller, Michael Kalz, Xuewei Wu, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Hemasphere|April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaJan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Nature Medicine|July 1, 2026
Clinical decision support in hematological malignancies using a case-grounded AI agentJulian Zoller, Michael Kalz, Xuewei Wu, et al.
Pageof 1